Proteasomal inhibition by alpha-synuclein filaments and oligomers
- PMID: 14711827
- DOI: 10.1074/jbc.M306390200
Proteasomal inhibition by alpha-synuclein filaments and oligomers
Abstract
A unifying feature of many neurodegenerative disorders is the accumulation of polyubiquitinated protein inclusions in dystrophic neurons, e.g. containing alpha-synuclein, which is suggestive of an insufficient proteasomal activity. We demonstrate that alpha-synuclein and 20 S proteasome components co-localize in Lewy bodies and show that subunits from 20 S proteasome particles, in contrast to subunits of the 19 S regulatory complex, bind efficiently to aggregated filamentous but not monomeric alpha-synuclein. Proteasome binding to insoluble alpha-synuclein filaments and soluble alpha-synuclein oligomers results in marked inhibition of its chymotrypsin-like hydrolytic activity through a non-competitive mechanism that is mimicked by model amyloid-Abeta peptide aggregates. Endogenous ligands of aggregated alpha-synuclein like heat shock protein 70 and glyceraldehyde-6-phosphate dehydrogenase bind filaments and inhibit their anti-proteasomal activity. The inhibitory effect of amyloid aggregates may thus be amenable to modulation by endogenous chaperones and possibly accessible for therapeutic intervention.
Similar articles
-
beta-Synuclein reduces proteasomal inhibition by alpha-synuclein but not gamma-synuclein.J Biol Chem. 2005 Mar 4;280(9):7562-9. doi: 10.1074/jbc.M412887200. Epub 2004 Dec 9. J Biol Chem. 2005. PMID: 15591046
-
UCH-L1 aggresome formation in response to proteasome impairment indicates a role in inclusion formation in Parkinson's disease.J Neurochem. 2004 Jul;90(2):379-91. doi: 10.1111/j.1471-4159.2004.02485.x. J Neurochem. 2004. PMID: 15228595
-
Aggregated and monomeric alpha-synuclein bind to the S6' proteasomal protein and inhibit proteasomal function.J Biol Chem. 2003 Apr 4;278(14):11753-9. doi: 10.1074/jbc.M208641200. Epub 2003 Jan 24. J Biol Chem. 2003. PMID: 12551928
-
Alpha synuclein in neurodegenerative disorders: murderer or accomplice?Nat Med. 1998 Jul;4(7):755-7. doi: 10.1038/nm0798-755. Nat Med. 1998. PMID: 9662355 Review. No abstract available.
-
[Recent neuropathology of parkinsonian syndromes].Rev Neurol (Paris). 2003 May;159(5 Pt 2):3S11-8. Rev Neurol (Paris). 2003. PMID: 12773883 Review. French.
Cited by
-
CSF α-synuclein improves diagnostic and prognostic performance of CSF tau and Aβ in Alzheimer's disease.Acta Neuropathol. 2013 Nov;126(5):683-97. doi: 10.1007/s00401-013-1148-z. Epub 2013 Jun 29. Acta Neuropathol. 2013. PMID: 23812319 Free PMC article.
-
Dysfunction of Cellular Proteostasis in Parkinson's Disease.Front Neurosci. 2019 May 10;13:457. doi: 10.3389/fnins.2019.00457. eCollection 2019. Front Neurosci. 2019. PMID: 31133790 Free PMC article. Review.
-
α-Synuclein in Parkinson's disease: causal or bystander?J Neural Transm (Vienna). 2019 Jul;126(7):815-840. doi: 10.1007/s00702-019-02025-9. Epub 2019 Jun 25. J Neural Transm (Vienna). 2019. PMID: 31240402 Review.
-
ELISA method to detect α-synuclein oligomers in cell and animal models.PLoS One. 2018 Apr 26;13(4):e0196056. doi: 10.1371/journal.pone.0196056. eCollection 2018. PLoS One. 2018. PMID: 29698510 Free PMC article.
-
Key genes and convergent pathogenic mechanisms in Parkinson disease.Nat Rev Neurosci. 2024 Jun;25(6):393-413. doi: 10.1038/s41583-024-00812-2. Epub 2024 Apr 10. Nat Rev Neurosci. 2024. PMID: 38600347 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous
